100 (PB088): KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mutations and KRAS wild-type amplifications.
A. Tedeschi, D.H. Peng, F. Schischlik-Siegl, O. Schaaf, D. Gerlach, F. Rocchetti, J. Popow, J. Broeker, T. Wunberg, A.S. Boghossian, M.G. Rees, M.M. Ronan, J.A. Roth, M. Williams, C. Vellano, J.R. Marszalek, T.P. Heffernan, M. Pearson, N. Kraut, R. Dorothea
{"title":"100 (PB088): KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mutations and KRAS wild-type amplifications.","authors":"A. Tedeschi, D.H. Peng, F. Schischlik-Siegl, O. Schaaf, D. Gerlach, F. Rocchetti, J. Popow, J. Broeker, T. Wunberg, A.S. Boghossian, M.G. Rees, M.M. Ronan, J.A. Roth, M. Williams, C. Vellano, J.R. Marszalek, T.P. Heffernan, M. Pearson, N. Kraut, R. Dorothea","doi":"10.1016/j.ejca.2024.114624","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"211 ","pages":"Article 114624"},"PeriodicalIF":7.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924013157","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
期刊介绍:
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.